Skip to main content
Premium Trial:

Request an Annual Quote

Med Fusion to Validate Clinical Utility of Theranostics Health Assays

NEW YORK (GenomeWeb News) – Med Fusion today said that it has inked a validation and market development pact with Theranostics Health aimed at validating the clinical utility of Theranostics Health's personalized medicine assays.

Through the collaboration, Med Fusion will help validate Theranostics Health's TheraLink Assays, which provide oncologists with a molecular map based on the unique pattern of aberrant signaling in each patient's cancer. The assays measure the activation status of signal transduction pathways that play a role in cancer growth and will enable oncologists to "exploit each tumor's individual molecular profile and therefore provide truly personalized treatment to each patient," Med Fusion said in a statement.

Lewisville, Texas-based Med Fusion, which runs an integrated reference testing lab and performs clinical trials as a service, will conduct clinical trials on the Theranostics Health assays along with other oncology practices associated with the firm. In addition, it will work with Rockville, Md.-based Theranostics Health on conducting promotional, marketing, sales efforts, and other activities aimed at the clinical services and trials, diagnostic, theranostic, and personalized healthcare markets.

Financial and other terms of the agreement were not disclosed.